Market Overview

Pluristem's Preclinical Results for PLX-RAD Cells Published in PLOS ONE


Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced today that preclinical results for its Placental eXpanded (PLX) RAD cells in the treatment of bone marrow disease have been published in peer reviewed journal PLOS ONE.

A study titled "Mitigation of lethal radiation syndrome in mice by intramuscular injection of 3D cultured adherent human placental stromal cells" was published on June 18th in the open access journal PLOS ONE ( This animal study on acute radiation syndrome (ARS) was performed by Professor Raphael Gorodetsky and his team at the Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology at Hadassah Medical Center, Jerusalem in collaboration and the support of Pluristem Therapeutics. The findings of the published study suggest that intramuscular treatment with Pluristem's PLX-RAD cells may serve as a highly effective "off the shelf" therapy to mitigate ARS.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (PSTI)

View Comments and Join the Discussion!